Zhejiang Tianyu Pharmaceutical made active pharmaceutical ingredients (API) with current good manufacturing practice (CGMP) deviations in impurity investigations and equipment cleaning.
What happened
FDA inspected the Zhejiang facility from February 28 to March 4, 2022, and found that the company had not extended impurity investigations to all potentially affected API lots and had released and distributed lots without mitigating controls. FDA also found that the company had not systematically evaluated its process for impurities, with one impurity found in 39 lots intended for the U.S. market, and that equipment had brown and black residue on product-contact surfaces. FDA said cleaning validation was not completed before starting-material batches were released, a repeat issue from a 2019 inspection.
What FDA found
The company did not extend its impurity investigation to all potentially affected API lots and continued to release and distribute lots without mitigating controls.
FD&C Act section 501(a)(2)(B)The company failed to systematically evaluate its manufacturing process and identify impurities, including a byproduct found in 39 lots intended for the U.S. market.
FD&C Act section 501(a)(2)(B)The company failed to identify a starting-material impurity that was later reported in a customer complaint.
FD&C Act section 501(a)(2)(B)Equipment used in API synthesis had brown and black residue on product-contact surfaces, and a worn part likely leached metal into production.
FD&C Act section 501(a)(2)(B)The company released starting-material batches from 2020 to 2022 before completing cleaning validation, a repeat deviation from the 2019 inspection.
FD&C Act section 501(a)(2)(B)
What FDA wants
FDA tells Zhejiang Tianyu to correct the deviations and respond in writing within 15 working days with corrective actions, including retrospective impurity and cleaning assessments and risk/recall plans; if work is not complete, it must give reasons and a schedule. FDA strongly recommends a qualified CGMP consultant.
Who should pay attention
- drugmakers that use this company’s API in finished drugs
- brands and contractors sourcing API or starting materials from this site
- quality teams managing supplier qualification and impurity and cleaning controls
This is a summary. Read the original letter on fda.gov.